<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Agilent Technologies (A) — Investment Wiki</title>
  <meta name="description" content="Fundamental analysis of Agilent Technologies (A). Business model breakdown, revenue segments, valuation metrics, and investment thesis.">
  <meta property="og:title" content="Agilent Technologies (A) — Investment Wiki">
  <meta property="og:description" content="Fundamental analysis of Agilent Technologies (A). Business model breakdown, revenue segments, valuation metrics, and investment thesis.">
  <meta property="og:type" content="article">
  <meta name="robots" content="index, follow">
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><rect width='100' height='100' rx='20' fill='%236C5CE7'/><text x='50' y='68' font-family='Arial' font-size='55' font-weight='bold' fill='white' text-anchor='middle'>G</text></svg>">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="../../docs/docs-styles.css">
</head>
<body>

<div class="doc-container">

  <nav class="doc-breadcrumb">
    <a href="../../index.html">Home</a>
    <span class="sep">/</span>
    <a href="../index.html">Investment</a>
    <span class="sep">/</span>
    Agilent Technologies (A)
  </nav>

  <header class="doc-header">
    <h1 class="doc-title">Agilent Technologies (A)</h1>
    <div class="doc-meta">
      <span class="tag">Company Analysis</span>
      <span>Investment Wiki — Fundamentals</span>
    </div>
  </header>

  <div class="doc-abstract">
    Agilent Technologies (A) is a global leader in life sciences, diagnostics, and applied chemical markets. Originally spun off from Hewlett-Packard in 1999, Agilent has transformed into a pure-play life sciences tools company. It provides analytical instruments, services, consumables, and expertise to laboratories worldwide, focusing on high-growth areas like biopharma, clinical diagnostics, and applied chemical markets.
  </div>

  <div class="doc-content">

    <div class="gab-stack-infobox">
      <div class="infobox-header">Quick Reference</div>
      <table>
        <tr><td>Ticker</td><td>A</td></tr>
        <tr><td>Sector</td><td>Healthcare (Life Sciences Tools)</td></tr>
        <tr><td>Market Cap</td><td>~$38 Billion</td></tr>
        <tr><td>P/E Ratio</td><td><span class="complexity-low">~25x</span></td></tr>
        <tr><td>Revenue Growth</td><td>~5-7% (Normalized)</td></tr>
        <tr><td>Operating Margin</td><td><span class="complexity-high">~27%</span></td></tr>
      </table>
    </div>

    <section class="doc-section">
      <h2>1.0 Business Overview</h2>

      <p>Agilent operates through three primary segments, each serving distinct customer needs within the laboratory ecosystem.</p>

      <h3>Life Sciences and Applied Markets Group (LSAG)</h3>
      <p>The core hardware business. This segment provides application-focused solutions including:</p>
      <ul>
        <li><strong>Chromatography & Mass Spectrometry:</strong> Liquid chromatography (LC) and mass spec (MS) systems used for separating and analyzing chemical components.</li>
        <li><strong>Spectroscopy:</strong> Atomic and molecular spectroscopy instruments.</li>
        <li><strong>Customers:</strong> Pharmaceutical and biotech companies, chemical and energy firms, food safety labs, and environmental testing facilities.</li>
      </ul>

      <h3>Agilent CrossLab Group (ACG)</h3>
      <p>The recurring revenue engine. This segment focuses on the entire lab ecosystem to improve customer outcomes:</p>
      <ul>
        <li><strong>Services & Consumables:</strong> Maintenance, repair, and compliance services, along with columns and sample preparation products.</li>
        <li><strong>Enterprise Lab Management:</strong> Software and services to optimize lab operations.</li>
        <li><strong>Moat:</strong> High switching costs and a large installed base drive sticky, high-margin recurring revenue.</li>
      </ul>

      <h3>Diagnostics and Genomics Group (DGG)</h3>
      <p>The high-growth potential segment. Includes:</p>
      <ul>
        <li><strong>Pathology:</strong> Immunohistochemistry (IHC) solutions for cancer diagnostics.</li>
        <li><strong>Companion Diagnostics (CDx):</strong> Tests developed in collaboration with pharma partners to identify patients for specific therapies.</li>
        <li><strong>Nucleic Acid Synthesis (NAS):</strong> Manufacturing of oligonucleotides for therapeutics.</li>
      </ul>
    </section>

    <section class="doc-section">
      <h2>2.0 Financial Performance</h2>

      <h3>Operational Efficiency</h3>
      <p>Agilent is known for its operational discipline and strong margins. The "build and buy" strategy has allowed it to expand its portfolio while maintaining profitability.</p>
      <ul>
        <li><strong>Margins:</strong> Consistent operating margin expansion, driven by the high-margin CrossLab business and operational improvements.</li>
        <li><strong>Capital Allocation:</strong> Balanced approach including share buybacks, dividends, and strategic M&A (e.g., the acquisition of BioTek).</li>
      </ul>

      <h3>Key Metrics</h3>
<pre><code><span class="code-label">reference</span>Gross Margin:      ~50-54%
Operating Margin:  ~27% (Adjusted)
ROE:               ~19%

Key Driver: The shift towards higher recurring revenue (ACG) reduces cyclicality
and supports valuation multiples.</code></pre>

    </section>

    <section class="doc-section">
      <h2>3.0 Valuation</h2>

      <p>Agilent typically trades at a premium to the broader market, reflecting its quality, recurring revenue base, and position in the critical healthcare infrastructure.</p>

      <h3>Valuation Metrics</h3>
      <table>
        <thead>
          <tr><th>Metric</th><th>Typical Range</th><th>Interpretation</th></tr>
        </thead>
        <tbody>
          <tr><td><strong>P/E Ratio</strong></td><td>22x – 28x</td><td>Premium valuation due to stability and quality.</td></tr>
          <tr><td><strong>ROE</strong></td><td>18% – 20%</td><td>Strong return on equity indicating efficient capital use.</td></tr>
          <tr><td><strong>FCF Yield</strong></td><td>3% – 4%</td><td>Healthy cash generation supports dividends and buybacks.</td></tr>
        </tbody>
      </table>

      <div class="callout callout-note">
        Valuation is sensitive to the "instrument replacement cycle" in pharma. During downturns, P/E may compress, offering potential entry points for long-term investors.
      </div>
    </section>

    <section class="doc-section">
      <h2>4.0 Risks</h2>

      <h3>China Exposure</h3>
      <p>A significant portion of Agilent's revenue (historically ~20%) comes from China. This exposes the company to geopolitical risks and local economic slowdowns, which can lead to volatility in quarterly results.</p>

      <h3>Pharma Spending Cycles</h3>
      <p>While the CrossLab business provides stability, the instrument side (LSAG) is cyclical. When pharmaceutical and biotech companies tighten their capital expenditure budgets, instrument sales can slow down significantly.</p>

      <h3>Competition</h3>
      <p>The life sciences tools market is highly competitive. Key rivals include:</p>
      <ul>
        <li><strong>Thermo Fisher Scientific (TMO):</strong> The industry giant with a massive portfolio.</li>
        <li><strong>Waters Corporation (WAT):</strong> A direct competitor in liquid chromatography and mass spec.</li>
        <li><strong>Danaher (DHR):</strong> A diversified conglomerate with strong positions in diagnostics and life sciences.</li>
      </ul>
    </section>

    <section class="doc-section">
      <h2>5.0 Related Pages</h2>

      <div class="integration-grid">
        <div class="integration-card">
          <h4><a href="../price-to-earnings-ratio.html">P/E Ratio</a></h4>
          <p>Analyze the valuation multiple assigned to Agilent's earnings.</p>
        </div>
        <div class="integration-card">
          <h4><a href="../return-on-equity.html">Return on Equity (ROE)</a></h4>
          <p>Understand how effectively Agilent uses shareholder capital.</p>
        </div>
        <div class="integration-card">
          <h4><a href="../free-cash-flow.html">Free Cash Flow</a></h4>
          <p>Agilent's strong FCF supports its capital allocation strategy.</p>
        </div>
      </div>
    </section>

  </div>

  <footer class="doc-footer">
    <a href="../index.html">← Back to Investment Wiki</a>
    <span style="color: var(--text-tertiary);">Investment Wiki</span>
  </footer>

</div>

</body>
</html>
